Media headlines about Tocagen (NASDAQ:TOCA) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Tocagen earned a coverage optimism score of 0.05 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.6752075802614 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Separately, Zacks Investment Research downgraded Tocagen from a “hold” rating to a “sell” rating in a research report on Tuesday, August 15th.

Shares of Tocagen (TOCA) traded down $0.02 during trading on Monday, reaching $11.92. The company had a trading volume of 139,400 shares, compared to its average volume of 146,714. Tocagen has a 52-week low of $8.60 and a 52-week high of $17.95. The company has a debt-to-equity ratio of 0.07, a quick ratio of 6.03 and a current ratio of 6.03.

Tocagen (NASDAQ:TOCA) last issued its earnings results on Wednesday, November 8th. The company reported ($0.50) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.02). The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.01 million. equities research analysts predict that Tocagen will post -2.88 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/04/tocagen-toca-given-media-impact-score-of-0-05.html.

Tocagen Company Profile

Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.

Insider Buying and Selling by Quarter for Tocagen (NASDAQ:TOCA)

Receive News & Stock Ratings for Tocagen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen Inc and related stocks with our FREE daily email newsletter.